Method for preventing or treating M tuberculosis infection

• US 9,655,958 B2
• Filed: 01/23/2015
• Issued: 05/23/2017
• Est. Priority Date: 04/29/2005
• Status: Expired due to Fees

• Current Assignee: Glaxosmithkline Biologicals SA (GSK plc)
• Original Assignee: Glaxosmithkline Biologicals SA (GSK plc)
• Inventors: Reed, Steven, Lobet, Yves, Marchand, Martine, Coler, Rhea
• Primary Examiner(s): Swartz, Rodney P
• Application Number:
  US14/603,935
• Publication Number:
  US 20150231224A1
• Time in Patent Office: 851 Days
• CPC Class Codes: A61K 2039/523 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 31/4409 only substituted in position 4, e.g. isoniazid, iproniazid
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 39/04 Mycobacterium, e.g. Mycobacterium tuberculosis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/35 from Mycobacteriaceae (F)

Abstract

The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Claims

1. A method for treating a subject infected with Mycobacterium tuberculosis comprising administering to a subject infected with M. tuberculosis

(a) a component selected from the group consisting of:

(i) a pharmaceutical composition comprising an adjuvant and an immunologically effective amount of a Mtb72f fusion protein selected from the group consisting of;

SEQ ID NO;

2 and SEQ ID NO;

4;

or

(ii) a nucleic acid encoding a Mtb72f fusion protein of (i); and

(b) one or more chemotherapeutic agents effective against a M. tuberculosis infection,

wherein the component of (a) induces an immune response against M. tuberculosis in the subject.